polaris
Jul 23, 2026

Trump Reveals 9 More Drug-Pricing Deals as Admin Expands Most-Favored-Nation Strategy

Article image

WASHINGTON

— President Donald Trump announced nine additional pharmaceutical agreements under his administration's most-favored-nation drug pricing strategy, aimed at aligning domestic prescription costs with lower prices paid in other developed nations. 

The August 31 announcement expands the administration's pricing framework to 26 total manufacturers, which the White House asserts now covers 89 percent of the branded prescription drug market. 

I. Expansion of Pricing Agreements and Medicaid Access

The nine newly participating mid-sized pharmaceutical and biotechnology companies are Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB. 

Under the terms of the agreements, these companies will provide most-favored-nation pricing access to every state Medicaid program for their manufactured products. The administration says the covered treatments involve hemophilia, Parkinson’s disease, glaucoma, macular degeneration, liver disease, skin conditions, and various cancers. Additionally, the deals guarantee most-favored-nation pricing for new innovative medicines introduced by these companies in the United States.

President Trump presented the expansion as a decisive measure to lower prescription costs, with the White House Council of Economic Advisers projecting approximately 600 billion dollars in savings over the next decade.

Other posts